ANI Pharmaceuticals is expected to report Q2 2026 revenue of $260.13 million and adjusted EPS of $2.04, with the stock trading at approximately $80.06, significantly below the $114.58 average analyst price target.
Investors are primarily focused on the commercial trajectory of Purified Cortrophin Gel following the mid-2026 deployment of a 90-person specialized sales force for the acute gouty arthritis indication.
Management recently raised its full-year 2026 revenue guidance to over $1 billion, driven by the high-margin Rare Disease segment which is now projected to represent 60% of total revenues.
Integration of eye treatments ILUVIEN and YUTIQ continues to be a key tailwind as ANI transforms from a generics player into a specialty biopharma leader.